Sales of the Swiss firm’s Zevtera are set to rocket after the beta-lactam antibiotic got approval from the US Food and Drug Administration. Now Basilea needs to sign up a commercial partner.

The sustainability of drugs that protect against antimicrobial resistance is on the edge without proper pull incentive models on a global scale. GARDP, Shionogi and a physician focused on infectious diseases explained why at a recent briefing in Tokyo.

User fee goal dates in April include four novel agents with breakthrough therapy designations, including Pfizer’s hemophilia B gene therapy and Immunity Bio’s IL-15 superagonist complex for bladder cancer.

Deal Snapshot: Novartis partnered with IFM Due in 2019 and has now exercised an option to buy the IFM Therapeutics subsidiary, continuing its ongoing relationship with the group.